Treatable massive pericardial effusion and hypertrophic cardiomyopathy in an infant with a novel homozygous ACADVL mutation: A case report
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- MEDICINE97(20) · 2018
- 피인용
- Web of Science 3Scopus 3
- FWCI (Scopus)
- 0.12
- JCR IF
- JCR 2017 2.028
- ISSN
- 0025-7974
저자
- Kim, Yoo-Mi제1저자교신저자Department of Pediatrics, College of Medicine, Chungnam National University Hospital, Jung-gu, Deajeon, South Korea
- 김지나Department of Pediatrics, College of Medicine, Pusan National University Children's Hospital, Yangsan, South Korea
- 고훈Department of Pediatrics, College of Medicine, Pusan National University Children's Hospital, Yangsan, South Korea
- Yoo, Han-WookMedical Genetics Center, Asan Medical Center Children's Hospital, University of Ulsan, College of Medicine, Seoul, South Korea
- 이형두Department of Pediatrics, College of Medicine, Pusan National University Children's Hospital, Yangsan, South Korea
초록
Rationale:Infantile-onset hypertrophic cardiomyopathy (HCMP) should be considered a largely genetic condition, although its onset is most often triggered by infection. Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is a rare autosomal recessive inborn error of mitochondrial fatty acid -oxidation that often causes severe cardiomyopathy and/or sudden death during the neonatal period.Patient concerns:Herein, we report an infant with VLCAD deficiency who presented with severe cardiac manifestations, including massive pericardial effusion and HCMP. The subject's older sister died of unknown causes at three days of age; however, the subject exhibited a normal tandem mass-spectrometry profile during the neonatal period.Diagnoses:During her later cardiac presentation, the subject's C-14 and C-18 levels became elevated, and she was determined, via the conducted molecular analysis, to harbor a novel homozygous frameshift mutation (c.103_112dup) in ACADVL.Interventions:After VLCAD deficiency diagnosis, the subject was treated with the administration of a medium chain triglyceride formula and fluid therapy.Outcomes:The subject's cardiac status was markedly improved by the dietary intervention and fluid therapy.Lessons:This report highlights that genetic mutations should be investigated as possible causes of infantile-onset HCMP, and that early diagnosis and intervention can prevent mortality for patients with VLCAD deficiency.
키워드
cardiomyopathylong chain acyl-CoA dehydrogenasemedium chain triglyceridemitochondrial -oxidationtandem mass screeningFATTY-ACID OXIDATIONCOA DEHYDROGENASE-DEFICIENCYVLCAD DEFICIENCYSUDDEN-DEATHINDIVIDUALSMANAGEMENTDISORDERSDIAGNOSISOUTCOMESDEFECTS
식별자
- Scopus EID
- 2-s2.0-85047363837
- WoS UID
- 000434305900063



로그인
연구물 목록으로